Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Aiolos Bio logo — company profile

Aiolos Bio

Founded 2023 United States San Francisco, United States 3 employees Series A Total: $245.00M Biopharma, Biotechnology +1

General Information

Company Name Aiolos Bio
Founded Year 2023
Location United States San Francisco, United States
Employees 3
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, B2C, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Aiolos Bio. To contact Aiolos Bio, visit aiolosbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aiolos Bio compare?

A PDF of Aiolos Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aiolos Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aiolos Bio

Aiolos Bio, founded in 2023, is a promising biopharmaceutical startup revolutionizing treatment approaches for respiratory diseases and immunological disorders. Based in the San Francisco Bay Area with additional operations in London, UK, the company is focused on developing an innovative anti-TSLP therapy that holds best-in-class potential.

Operating within the Biopharma, Biotechnology, and Health Care industries, Aiolos Bio benefits from a team of experienced drug developers. These professionals have a track record of successful therapeutics in immune-related conditions such as asthma and rheumatoid arthritis. Their expertise positions the company to make a significant impact on patient care by reducing treatment burdens.

The company recently secured a substantial $245M Series A investment on 24 October 2023, backed by key players like Atlas Venture, RA Capital Management, Forbion, Sofinnova Investments, and Bain Capital Life Sciences. This strategic funding reinforces its journey towards transformative therapeutic solutions.

Business keywords: biopharma, respiratory disease, immunological disorders, drug development, clinical stage, San Francisco Bay area, London operations, anti-TSLP therapy, immune conditions, asthma, rheumatoid arthritis, IPF, clinical trials, patient-centric therapy

Services & Products

Medicine Development
Vaccine Delivery
Scientific Research
Health Security Solutions

Target Customers

Patients Healthcare Professionals Investors Global Health Organizations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $245.00M 5
Atlas Venture RA Capital Management Forbion
Atlas Venture, RA Capital Management +3
24 Oct 2023

Latest News

View All
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy — Thenextweb
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
Thenextweb Jan 11, 2025

Aiolos Bio Alternatives & Competitors

View All Alternatives
Aiolos Bio vs
Upstream Bio
Upstream Bio United States

Developing treatments for inflammatory diseases

IPO
78 employees
Biotechnology, Health Care
Aiolos Bio vs
ACELYRIN, INC.
ACELYRIN, INC. United States

We are a late-stage clinical biopharma company focused on providing life-changing new treatment opti...

Acquired
103 employees
Biopharma, Biotechnology
Aiolos Bio vs
Cyxone
Cyxone Sweden

Life-changing treatments for disorders of the immune system

11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Aiolos Bio

At Aiolos Bio, we are dedicated to revolutionizing the treatment landscape for respiratory disease and other immunological disorders. Our goal is to provide patients and caregivers with more efficacious therapies that significantly reduce treatment burden. Our vision is embodied in our current focus...
Aiolos Bio was founded in 2023.
Aiolos Bio is headquartered in San Francisco, United States.
Aiolos Bio operates in Biopharma, Biotechnology and Health Care. Its work centres on biopharma, respiratory disease, immunological disorders and drug development. Its customers include Patients, Healthcare Professionals and Investors.
Aiolos Bio has a B2B, B2C and B2D business model. Its revenue comes from Licensing and Product Sales.
Aiolos Bio has approximately 3 employees.
Aiolos Bio has completed 1 funding round, raising a total of $245.00M. The latest funding stage is Series A.
Aiolos Bio offers: Medicine Development, Vaccine Delivery, Scientific Research, Health Security Solutions.
Top alternatives and competitors to Aiolos Bio include Upstream Bio, ACELYRIN, INC., Cyxone, Iovance Biotherapeutics, Inc., SetPoint Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aiolos Bio and Upstream Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aiolos Bio, https://bouncewatch.com/company/aiolos-bio, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes